Cargando…

Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer

Stage III–IV non-small cell lung cancer (NSCLC) is a devastating disease characterized by a poor prognosis. NSCLC tumors carry genetic mutations, which can lead to the expression of altered protein sequences. Peptides originating from mutated proteins and bound to MHC molecules on the tumor cell sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosting, Linette T., Franke, Katka, Martin, Michael V., Kloosterman, Wigard P., Jamieson, Jennifer A., Glenn, Laura A., de Jager, Miranda W., van Zanten, Jacoba, Allersma, Derk P., Gareb, Bahez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322189/
https://www.ncbi.nlm.nih.gov/pubmed/35890409
http://dx.doi.org/10.3390/pharmaceutics14071515
_version_ 1784756236915310592
author Oosting, Linette T.
Franke, Katka
Martin, Michael V.
Kloosterman, Wigard P.
Jamieson, Jennifer A.
Glenn, Laura A.
de Jager, Miranda W.
van Zanten, Jacoba
Allersma, Derk P.
Gareb, Bahez
author_facet Oosting, Linette T.
Franke, Katka
Martin, Michael V.
Kloosterman, Wigard P.
Jamieson, Jennifer A.
Glenn, Laura A.
de Jager, Miranda W.
van Zanten, Jacoba
Allersma, Derk P.
Gareb, Bahez
author_sort Oosting, Linette T.
collection PubMed
description Stage III–IV non-small cell lung cancer (NSCLC) is a devastating disease characterized by a poor prognosis. NSCLC tumors carry genetic mutations, which can lead to the expression of altered protein sequences. Peptides originating from mutated proteins and bound to MHC molecules on the tumor cell surface are referred to as neoantigens, as they are tumor-specific and not expressed in normal cells. Due to their tumor specificity, neoantigens have a strong potential to induce an anti-tumor immune response and have been investigated for development of personalized therapeutic cancer vaccines. The current study describes the development of a clinical grade neoantigen vaccine formulation (FRAME-001) intended as immunotherapy in advanced NSCLC in combination with the immune checkpoint inhibitor pembrolizumab. The detection of aberrant tumor-specific transcripts as well as an algorithm to select immunogenic neoantigen peptides are described. Subsequently, selected neoantigen peptides were synthesized with a high throughput synthesis platform and aseptically formulated under good manufacturing practice (GMP) conditions into four aqueous peptides mixtures that each contained six neoantigen peptides. A validated stability-indicating analytical method was developed in which we considered the personalized nature of the formulation. An extensive stability study performed either at −25 °C or −80 °C showed that the formulation was stable for up to 32 weeks. The formulation was mixed with the vaccine adjuvant Montanide ISA 51 VG, which yielded the final vaccine emulsion. The stability of the vaccine emulsion was demonstrated using microscopic examination, differential light scattering, and the water-drop test. The presented data show that FRAME-001 is a feasible personalized vaccine formulation for the treatment of stage III–IV NSCLC. The presented data may give guidance in the development of novel personalized therapeutic vaccines since this formulation strategy could be used for any cancer indication.
format Online
Article
Text
id pubmed-9322189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93221892022-07-27 Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer Oosting, Linette T. Franke, Katka Martin, Michael V. Kloosterman, Wigard P. Jamieson, Jennifer A. Glenn, Laura A. de Jager, Miranda W. van Zanten, Jacoba Allersma, Derk P. Gareb, Bahez Pharmaceutics Article Stage III–IV non-small cell lung cancer (NSCLC) is a devastating disease characterized by a poor prognosis. NSCLC tumors carry genetic mutations, which can lead to the expression of altered protein sequences. Peptides originating from mutated proteins and bound to MHC molecules on the tumor cell surface are referred to as neoantigens, as they are tumor-specific and not expressed in normal cells. Due to their tumor specificity, neoantigens have a strong potential to induce an anti-tumor immune response and have been investigated for development of personalized therapeutic cancer vaccines. The current study describes the development of a clinical grade neoantigen vaccine formulation (FRAME-001) intended as immunotherapy in advanced NSCLC in combination with the immune checkpoint inhibitor pembrolizumab. The detection of aberrant tumor-specific transcripts as well as an algorithm to select immunogenic neoantigen peptides are described. Subsequently, selected neoantigen peptides were synthesized with a high throughput synthesis platform and aseptically formulated under good manufacturing practice (GMP) conditions into four aqueous peptides mixtures that each contained six neoantigen peptides. A validated stability-indicating analytical method was developed in which we considered the personalized nature of the formulation. An extensive stability study performed either at −25 °C or −80 °C showed that the formulation was stable for up to 32 weeks. The formulation was mixed with the vaccine adjuvant Montanide ISA 51 VG, which yielded the final vaccine emulsion. The stability of the vaccine emulsion was demonstrated using microscopic examination, differential light scattering, and the water-drop test. The presented data show that FRAME-001 is a feasible personalized vaccine formulation for the treatment of stage III–IV NSCLC. The presented data may give guidance in the development of novel personalized therapeutic vaccines since this formulation strategy could be used for any cancer indication. MDPI 2022-07-21 /pmc/articles/PMC9322189/ /pubmed/35890409 http://dx.doi.org/10.3390/pharmaceutics14071515 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oosting, Linette T.
Franke, Katka
Martin, Michael V.
Kloosterman, Wigard P.
Jamieson, Jennifer A.
Glenn, Laura A.
de Jager, Miranda W.
van Zanten, Jacoba
Allersma, Derk P.
Gareb, Bahez
Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
title Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
title_full Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
title_fullStr Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
title_full_unstemmed Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
title_short Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer
title_sort development of a personalized tumor neoantigen based vaccine formulation (frame-001) for use in a phase ii trial for the treatment of advanced non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322189/
https://www.ncbi.nlm.nih.gov/pubmed/35890409
http://dx.doi.org/10.3390/pharmaceutics14071515
work_keys_str_mv AT oostinglinettet developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT frankekatka developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT martinmichaelv developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT kloostermanwigardp developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT jamiesonjennifera developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT glennlauraa developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT dejagermirandaw developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT vanzantenjacoba developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT allersmaderkp developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer
AT garebbahez developmentofapersonalizedtumorneoantigenbasedvaccineformulationframe001foruseinaphaseiitrialforthetreatmentofadvancednonsmallcelllungcancer